Navigation Links
BioMS Medical Announces 2007 Year End Results
Date:3/18/2008

tudy

was initiated in June, 2007 and to date there has been in excess of

200 patients enrolled. The trial will include approximately 510

patients at approximately 65 sites across the U.S. The DSMB has

conducted its first review of the data from this trial and has

recommended it continue. The trial is expected to complete enrollment

in mid-2008.

- MINDSET-01: A phase II clinical trial evaluating MBP8298 for the

treatment of relapsing-remitting MS ("RRMS"). The randomized,

double-blind study has completed recruitment with 218 patients

enrolled at 24 trial sites in 6 countries across Europe. The DSMB has

completed three safety analyses to date and recommended that the

trial continue as per the protocol.

Licensing and Development Agreement

On December 17, 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to its lead MS compound, MBP8298. Under the terms of the agreement, Lilly and BioMS will collaborate on the development of MBP8298 and will also share in certain development costs with Lilly being responsible for future research and development, manufacturing and marketing activities. The transaction closed on January 25, 2008 with the receipt of an upfront payment of US$87 million. BioMS has the potential to receive additional development and sales milestones of up to US$410 million and escalating royalties on sales commensurate with the current stage of development of the product if MBP8298 is commercialized. BioMS will continue to oversee the current trials. The completion of the transaction resulted in licensing bonuses, as contemplated in a number of pre-existing employment agreements, paid to all Company personnel in February 2008 of $9.0 million which was reviewed and approved by the independent Compensation Committee, and supported by an independent compensation
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at BioContact 2007
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. GHI Medical Deploys New Test to Help Determine Hair Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
(Date:7/29/2015)... San Bruno, CA. (PRWEB) , ... July 29, ... ... partnership agreement with PRC Clinical, a Silicon Valley-based CRO specializing in ... FDA advisory services, and patient recruitment services. The core expertise of PRC Clinical ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study ... from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... providing protection, Costello also balanced socio-economic and environmental needs and concerns. The ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... the company is making good progress in evaluating the full range of capabilities ... stem cells. Adult tissue stem cells perform the day-to-day renewal and repair of ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... BRANFORD, Conn., Aug. 5 Marinus Pharmaceuticals, a,developer ... pain disorders, has appointed John Krayacich as president,and ... for leading,the company,s drug and business development for ... II, and chelerythrine, a pre-clinical,schizophrenia candidate., Mr. ...
... of $14.9 million -- Record revenues from domestic MIS products - $5.1 ... -- Net loss improves ... -- Reported MIS procedure times of 60 minutes and hospital stays of two ... days or less, WEST CHESTER, Ohio, Aug. 5 ...
... Deliver Faster Recovery,Fewer Complications for Patients Requiring ... Thoracic Group, P.A., (http://www.thoracicgroup.com ), a ... national leader of minimally-invasive video assisted thoracic ... its 5,000th VATS,surgical procedure. Highly beneficial in ...
Cached Biology Technology:Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 2Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 3Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 4AtriCure Reports Record Second Quarter 2008 Financial Results 2AtriCure Reports Record Second Quarter 2008 Financial Results 3AtriCure Reports Record Second Quarter 2008 Financial Results 4AtriCure Reports Record Second Quarter 2008 Financial Results 5AtriCure Reports Record Second Quarter 2008 Financial Results 6AtriCure Reports Record Second Quarter 2008 Financial Results 7AtriCure Reports Record Second Quarter 2008 Financial Results 8Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure 2Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure 3
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... children transform into adults some of the genes involved in ... study of more than 500 pairs of twins. , The ... that changes in gene expression between ages 14 and 18 ... variation that occurred by age 18, says Dr. Harold Snieder, ...
... The wood shavings from sawmills can be used to produce ... containers. Moreover, this substrate has the advantage that it can ... such as peat or coconut fibre. , These are ... who, jointly with the Aralur company in Ziordia (Navarre), have ...
... sexually active teenage girls know relatively little about sexually ... to a paper by Carnegie Mellon University researchers that ... Journal of Adolescent Health. , "For the most part ... getting diagnosed with them," said Julie Downs, lead author ...
Cached Biology News:Genes affecting blood pressure change as children become adults 2New organic substrate 2Teens unaware of sexually transmitted diseases until they catch one, Carnegie Mellon study finds 2
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
... Molecular Probes is pleased to offer ... the ultrasensitive detection of primary amines. ... Indiana University, the ATTO-TAG reagents are ... (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all ...
Biology Products: